

The IFCC committee on EQA and Proficiency Testing (IFCC C-PT)
Major Objectives and New Projects

Dr Alexander Haliassos
MD, PhD, EuSpLM
Chair IFCC Committee on proficiency testing (C-PT),
Greek Proficiency Testing Scheme for Clinical Laboratories (ESEAP)



### IFCC Committee on Proficiency Testing Introduction

The role of Proficiency Testing schemes (or External Quality Assurane programs) is of primordial importance:

- to the analytical quality,
- to the standardization of the methods and
- to the harmonization of the results,
   but there is a lack of interest from the commercial providers of such schemes
- for the more new and complex tests and
- for the very old and simple measurands that involve a new calibration curve, because of the very subtle problems induced at the interpretation of the statistical results of their, already well-established and running, schemes.

# IFCC Committee on Proficiency Testing Objectives

- The C-PT is a multidisciplinary effort in the analysis and the exploration of the Proficiency Testing issues. Our aims are:
  - To facilitate the introduction of international proficiency testing schemes for uncommon but clinically important measurands (analytes).
  - To use the information to select measurands (analytes) that may be suitable for method harmonization as a means to improving patient outcomes.

### Main project of the C-PT

- Is the creation of an online database web application accessible via web browsers and via specific applications for the major mobile platforms.
- The roots of this database will be the analytes (tests, measurands) that will be filed with all possible synonyms ("official" from the C-NPU) as also as the methods (assays, instruments, reagents etc.) also with all possible synonyms.
- Another part of the DB, maintained with the cooperation of the C-AQ, will be the EQA-PT providers section containing all their contact information, their programs with the analytes, frequencies, type of statistics, commutability of control materials, their accreditation or certification status etc.
- All register users can add any term in the database, although the application will propose similar ones if there are already filed, searching all synonyms.
- Finally, they can "vote" expressing their desire for the introduction of a PT for this analyte.

### Online Database or Web Application

Developed as web application, as opposed to classic website provides:

- Capabilities:
  - Optimized for smartphones, tablets and desktop
  - Responsive
  - Adapts to the screen size
  - Modern and fast
  - Mobile app ready
- Features:
  - Left pane navigation
  - Public area
  - Admin area (login required)
  - Switch languages

# Flowchart of the Online Database Web Application

I want to see if an
 EQA/PT exist for an
 analyte in which I am
 interested

2.
I want to nominate my EQA/PT
To be listed for an analyte,or
express interest to be involved
in setting up a pre EQA/PT

I want to express that I need an EQA/PT for an analyte for which none exists


4.
I want to have a text on
The Discussion Forum

Messages 2, 3 and 4 are forwarded to the IFCC Market Database Manager. He/she decided to Publish them on the website and if yes Homogenizes the format


6. Table with listing of information of Supply and Demand

Analyte	Supply (pre) EQA/PT		Demand EQA/PT				
	I have an EQA/PT in Place	I'm interested to be involved in pre EQA/PT	l'm a laboratory	I'm an EQA/PT organiser	l'm a Manufacturer	I'm none of these categories	Forum
X in Serum	INSTAND - DE	UKNEQAS - UK	Hospital X Beijing - CN	RCPA AU	Roche - DE	Goverment - GR	FDA - US

### Login Page: http://ptdb.ifcc.org



### Search for a PT provider - EQA organizer



#### Search Results Search: Show 10 \$ **Organizing Body** Country Website Email Info dmpeec@fba.org.ar Argentina Fundación Bioquímica Argentina www.fba.org.ar i Details Australia RCPA Quality Assurance Programs rcpaqap@rcpaqap.com.au www.rcpaqap.com.au i Details John.Stathopoulos@health.nsw.gov.au Australia **PaLMS** www.austox.com Austrian Society for Qualityy Assurance i Details and Standardization in Medical office@oequasta.at Austria www.oequasta.at Laboratories **i** Details N/A Bolivia Bulgarian Society for Quality Assurance Bulgaria www.beqas.org deskova@beqas.org in Medical Laboratory

www.ispch.cl

www.sekk.cz

Instituto de Salud Pública

SEKK

Chile

Czech

Republic


i Details


i Details

rgomez@ispch.cl

sekk@sekk.cz

### **Details of Search Results**





# Proficiency Testing (PT) schemes - External Quality Assurance (EQA) programs in Molecular Tests

- We organized an EQA program for the Cobas EGFR v2 mutation test in ctDNA of plasma in Greece for Liquid Biopsy samples.
- Launched under the auspices of the Laboratory of Circulating Tumor Cell Analysis (ACCT Laboratory) of the University of Athens by the Greek Proficiency Testing Scheme for Clinical Laboratories, (ESEAP - www.eseap.gr).
- This preliminary program was based on the distribution of 10 plasma samples (synthetic reference materials produced by Horizon Discovery, Cambridge, United Kingdom) to eight laboratories in Greece.
- Six of eight laboratories are accredited according to ISO 15189 for the EGFR mutation testing in tissues using methods such as COBAS, Vienna labs hybridization, DNA sequencing, and new generation sequencing (NGS).
- Moreover, three of them use human plasma as a sample matrix.

### **CCLM**

- Date of online publication September 29, 2018
- URL: https://doi.org/10.1515/cclm-2018-0676

**DE GRUYTER** 

Clin Chem Lab Med 2018; aop

#### Letter to the Editor

Aliki Ntzifa, Christos Kroupisa, Alexander Haliassosb and Evi Lianidouc,\*

## A pilot plasma-ctDNA ring trial for the Cobas® EGFR Mutation Test in clinical diagnostic laboratories

https://doi.org/10.1515/cclm-2018-0676 Received June 27, 2018; accepted August 20, 2018

**Keywords:** circulating tumor DNA; epidermal growth factor receptor (*EGFR*) mutations; external quality assessment (EQA); liquid biopsy; non-small cell lung carcinoma (NSCLC).

To the Editor,

Liquid biopsy based mainly on the analysis of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA)

accredited according to ISO17043 standard or in interlaboratory comparisons that are in substantial agreement with [4].

Epidermal growth factor receptor (*EGFR*) mutation testing is an established critical parameter in non-small cell lung carcinoma (NSCLC) tissues for therapeutic decisions according to the new era of personalized medicine. Nowadays, tissue genotyping for *EGFR* mutations has been well incorporated in clinical practice as a gold standard for therapeutic decisions and for early detection of recurrences or selection of tyrosine kinase inhibitors (TKI). However, major limitations emerge quite often: limited

# IFCC Committee on Proficiency Testing New Programs (I) Neopterin in CSF validation

- Target Molecule
- Neopterin is a pteridin implicated in the cell immune stimulation.
- Neopterin or D-erythro-Neopterin
- The L-*Threo*-Neoptein is called Monapterin.
- Empirical Formula (Hill Notation): C<sub>9</sub>H<sub>11</sub>N<sub>5</sub>O<sub>4</sub>
- Molecular Weight: 253.21
- CAS Number: 2009-64-5
- Human pteridins is a family of about 10 members: Biopterin, Neopterin and its isomer Monapterin, Lumazine, 6-0H biopterin, Xanthopterin, Pteric Acid...

# IFCC Committee on Proficiency Testing New Programs (I) Neopterin in CSF validation

- The neopterin controls prepared by a member of C-PT are very stable even at ambient temperature!
- We decided to distribute, tentatively before the end of 2019, a set of 8 vials (4 duplicates at clinically significant concentrations) to 15-20 laboratories around the world to measure during the next four months, using all available methods, as a pilot scheme. This program can be implemented easily because of the control samples stability.
- Using the results we will compare the measuring assays and afterwards we will forward them to the ICHLR (acronym for the International Consortium for Harmonization of Clinical Laboratory Results) to initiate the harmonization of measuring methods.

# IFCC Committee on Proficiency Testing New Programs (II) –EQA providers cooperation

- During the last two months, we started discussions with EQA-PT providers of neighboring countries.
- The C-PT proposes and supports the collaboration of EQA providers through the *simultaneous use of common control materials*, tailor made from accredited IVD manufacturer(s), and the *anonymized exchange of laboratory results*, including methods and instruments.
- This is a win-win situation that can greatly help participating EQA-PT providers giving them the possibility to use much bigger "peer groups" to calculate their target values, thus improving their accuracy and the quality of produced performance evaluations for the participating laboratories.
- We will try to implement this collaboration from the 2020 distributions.

